Terasaki Institute For Biomedical Innovation

Terasaki Institute For Biomedical Innovation, doing business as Terasaki Research Institute, is a nonprofit biomedical research organization based in Woodland Hills, California, that develops organ-on-chip platforms, engineered biomaterials, and personalized regenerative organ manufacturing technologies for the National Institutes of Health as both a prime grant recipient and, as of July 2026, as a prime awardee under an OTA vehicle. The institute operates primarily as a research recipient (55% of recent awards as prime) and as a subrecipient on collaborative NIH-funded grants (45% of awards), with no set-aside designations applicable to its nonprofit status.

Terasaki's federal footprint concentrates almost entirely within the NIH ecosystem, with 100% of its identified combined potential value anchored to NIH awards across ten distinct customer agencies at the NIH component level. The National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of General Medical Sciences are the primary funding sources. A single $19.8 million OTA vehicle issued July 31, 2026 — PROMETHEUS (Personalized & Regenerative Organ Manufacturing Enhanced Through Hypoimmunogenic Engineered Universal Cells), with ultimate completion July 30, 2031 — accounts for the vast majority of identified potential value and represents a structural shift from Terasaki's historical grant-only engagement toward alternative transaction authority. This OTA funds development of personalized regenerative organ manufacturing using hypoimmunogenic engineered universal cells, extending Terasaki's existing research portfolio in organ-on-chip platforms and immunomodulation.

Representative prime grant work includes a $492,250 Allergy and Infectious Diseases Research award (CFDA 93.855) issued February 2, 2026, for vascularized porcine liver on-a-chip modeling human xenoimmune responses toward pig-to-human liver xenografts, running through January 31, 2028; a $393,800 Biomedical Research and Research Training award (CFDA 93.859) issued September 5, 2026, for immunomodulatory nanofibrous modular aerogels targeting chronic wound healing in diabetic and pressure ulcers, with completion May 31, 2030; and an August 14, 2024 grant for vascularized liver-heart on-a-chip modeling antibody-mediated rejection and allograft tolerance, running through June 30, 2028. Activity has grown unevenly — one award in 2020, five in 2023, four in 2024, three in 2025, and three in 2026 — with four awards reaching ultimate completion within the next twenty-four months.

Terasaki functions as a subrecipient on collaborative grants with Mayo Clinic Arizona (recurring subrecipient relationship focused on biomaterial development for drug delivery, tissue regeneration, and microfluidic device integration, with sub-awards dating from November 2023 through July 2025), the University of Texas at Austin (robotic bioprinting for volumetric muscle loss, sub-awards from February 2023 through February 2025), and UCLA (blood-brain barrier and liver chip components on a multi-organ platform, sub-awards from January 2023 and January 2025). Across both prime and sub roles, Terasaki's capability portfolio centers on vascularized organ-on-chip systems modeling human immune response and allograft rejection mechanisms, engineered biomaterials for wound healing and drug delivery, 3D bioprinting technologies, and microfluidic device integration for tissue engineering and regenerative medicine applications. The institute's research agenda tracks directly to NIH priorities in organ transplantation, xenotransplantation, chronic wound management, and FDA Modernization Act 2.0 initiatives advancing organs-on-chips as preclinical and clinical translation platforms.